CareDx Launches VANTx AI Platform for Transplant Data Analytics and Announces $170M Lab Products Divestiture
Key Insights
CareDx unveiled VANTx (search), a first-of-its-kind AI-powered clinical data analytics platform designed to transform complex transplant data into actionable insights for clinical research and real-world evidence generation.
The company announced a $170 million divestiture of its Lab Products business to EuroBio Scientific (search), allowing strategic focus on core Testing Services and Patient and Digital Solutions.
CareDx reported strong Q1 2026 preliminary results with 48% year-over-year growth in Testing Services revenue and 17% growth in testing volume.
CareDx has launched VANTx (search), an AI-powered clinical data analytics platform designed to revolutionize transplant care research, while simultaneously announcing a strategic $170 million divestiture of its Lab Products business to focus on core precision medicine services.
AI Platform Transforms Transplant Data Analysis
The cloud-native VANTx (search) platform represents the first-of-its-kind solution for transplant program cohort analysis, clinical research, and real-world evidence generation. Announced at the 2026 Precision Medicine World Conference, the platform is designed for secure, scalable cohort analysis across longitudinal patient timelines, enabling evaluation of treatment trends, patient outcomes, and practice patterns.
"As the market leader in transplant precision diagnostics and patient care solutions, we can help our transplant center partners generate actionable insights using LLMs and other models," said Jing Huang, Chief Data and AI Officer at CareDx. "I joined CareDx to lead the development of the VANTx (search) platform and to help transplant teams and researchers make sense of complex, longitudinal data in a way that is intuitive, clinically meaningful, and actionable."
Technical Architecture and Capabilities
VANTx (search) operates on a live data pipeline of CareDx's continuously expanding, multidimensional data repository of de-identified molecular tests and clinical trial data. The platform can incorporate additional data at transplant centers' request, including EMR, care quality, and remote patient monitoring data.
The system is built on a Databricks environment that leverages the Llama 3 foundational model and other advanced machine-learning techniques optimized for structured clinical data. VANTx (search) will incorporate validated predictive and prognostic insights models from KOAR, SHORE, ALAMO, and MAPLE to support kidney, heart, lung, and liver transplant research, respectively.
These models are intended to inform sub-analyses of predicted disease risk in areas of significant research interest including delayed graft function (search), microvascular inflammation (search), antibody mediated rejection (search), cardiac allograft vasculopathy (search), and cancer (search) risk.
Strategic Business Restructuring
CareDx announced a definitive agreement to divest its Lab Products business to EuroBio Scientific (search) for $170 million in cash. The Lab Products business consists of IVD PCR kits for rapid deceased donor HLA (search) typing, IVD NGS-based kits for transplant recipient HLA typing globally, and IVD NGS-based monitoring assays for solid organ and stem cell transplant recipients outside North America.
"This divestiture allows us to strategically focus on our core Testing Services and Patient and Digital Solutions, where our solutions-selling strategy is working," said John Hanna, President and CEO of CareDx. "Having partnered with EuroBio Scientific (search) since 2014, we believe their global scale and broad IVD capabilities positions them well to execute the Lab Products business."
Transaction Details
The agreement includes several key provisions:
- Total consideration of $170 million in cash at closing
- CareDx to provide transition services for at least 6 months at EuroBio Scientific's expense
- EuroBio Scientific grants CareDx sole and exclusive perpetual rights to distribute post-transplant monitoring IVD tests in North America, including AlloSeq cfDNA
The transaction requires Swedish regulatory review and is anticipated to close by the end of CareDx's third quarter 2026.
Strong Financial Performance
CareDx reported preliminary first quarter 2026 financial results showing robust growth across key metrics:
- Total revenue of approximately $118 million, representing 39% year-over-year growth
- Testing Service volume of approximately 54,900, up 17% year-over-year
- Testing Service revenue of approximately $91 million, demonstrating 48% year-over-year growth
- Average revenue per test of approximately $1,660, including approximately $14 million in prior period revenue
- Patient and Digital Solutions revenue of approximately $16 million, up 33% year-over-year
- Cash, cash equivalents, and marketable securities of approximately $198 million as of March 31, 2026
The Lab Products business showed a 4% year-over-year decline to approximately $10 million in revenue, supporting the strategic rationale for divestiture.
Market Access and Implementation
VANTx (search) is currently available to transplant centers through consultation with CareDx's medical affairs team. The company plans to make the platform available through self-service permission-based access to clinicians later in 2026.
The platform is intended to support clinicians, transplant programs, and pharmaceutical partners in testing hypotheses to generate actionable findings for treatment protocol development, investigator-initiated studies, and clinical trial design.
CareDx expects to apply proceeds from the Lab Products divestiture toward investments supporting long-term growth strategy, including potential inorganic investments fitting its Precision Diagnostics Solutions model, and may include returning capital to shareholders.